{"id":"NCT00712348","sponsor":"Pfizer","briefTitle":"Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase","officialTitle":"A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase in Patients With Gaucher Disease Treated With Imiglucerase","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2013-04","completion":"2013-05","firstPosted":"2008-07-10","resultsPosted":"2014-06-05","lastUpdate":"2018-10-04"},"enrollment":31,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Gaucher Disease"],"interventions":[{"type":"DRUG","name":"Taliglucerase alfa","otherNames":["Plant cell expressed recombinant glucocerebrosidase (prGCD)"]}],"arms":[{"label":"Taliglucerase alfa","type":"EXPERIMENTAL"}],"summary":"This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (CerezymeÂ®) enzyme replacement therapy.","primaryOutcome":{"measure":"Hemoglobin","timeFrame":"Every 3 months from Baseline to Month 9","effectByArm":[{"arm":"Taliglucerase Alfa","deltaMin":13.5,"sd":1.4}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":10,"countries":["United States","Australia","Canada","Israel","Spain","United Kingdom"]},"refs":{"pmids":["24950666"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":31},"commonTop":["NASOPHARYNGITIS","INFUSION RELATED REACTION","ARTHRALGIA","HEADACHE","UPPER RESPIRATORY TRACT INFECTION"]}}